Bioidentical Hormone Therapy: The Complete Guide

Bioidentical hormone therapy is a form of menopausal hormone therapy that uses hormones with the same molecular structure as those the ovaries produce, chiefly 17-beta estradiol and progesterone. Clinicians prescribe it to relieve hot flashes and night sweats, restore sleep, treat vaginal and urinary symptoms, and slow the bone loss that accelerates around menopause. Bioidentical hormones come as FDA-approved products and as compounded preparations, in patches, gels, capsules, creams and vaginal forms. Root-cause practices such as Wellness Architecture in Menlo Park prescribe bioidentical hormone therapy alongside treatment of thyroid, blood sugar and nutrient problems, because hormones address only the symptoms that falling estrogen and progesterone cause.

Hormones Used in Bioidentical Therapy

Bioidentical hormone therapy relies on a small set of hormones, each with a distinct job in the menopause transition:

• 17-beta estradiol replaces the main estrogen the ovaries make before menopause. Estradiol drives most of the benefit: it reduces hot flashes and night sweats, protects bone density and restores vaginal tissue.
• Progesterone, usually as oral micronized progesterone, protects the uterine lining in women who take estrogen and still have a uterus. Taken at bedtime, oral micronized progesterone also has a sedating effect that many women notice in their sleep.
• Testosterone in low doses treats low sexual desire in postmenopausal women. Guideline support covers that indication specifically, and no testosterone product carries FDA approval for women in the United States.
• Estriol, a weaker estrogen, appears only in compounded preparations in the United States and has no FDA-approved product.
• Thyroid hormone, though not a sex hormone, often belongs in the same conversation: thyroid problems peak in the same decades and produce fatigue, weight gain and brain fog that estrogen does not correct.

Dose, form and combination vary with symptoms, health history and whether a woman has a uterus. Estradiol without progesterone suits only women who have had a hysterectomy.

Delivery Forms for Bioidentical Hormones

Delivery form determines how a hormone enters the bloodstream, how steady the levels stay and, for estrogen, how the liver responds. The main forms are:

1. Skin patches deliver estradiol through the skin, usually changed once or twice a week. Transdermal estradiol bypasses first-pass liver metabolism.
2. Gels and sprays also deliver estradiol through the skin, applied daily to the arm or thigh.
3. Oral capsules and tablets deliver estradiol or micronized progesterone by mouth. Oral estrogen passes through the liver first, which raises clotting factors. Bijuva, approved by the FDA in 2018, combines estradiol and progesterone in a single oral capsule.
4. Vaginal estrogen comes as low-dose tablets, creams and rings that treat vaginal dryness, painful sex and urinary symptoms with minimal absorption into the bloodstream.
5. Pellets are implanted under the skin and release hormones over several months. Pellets are compounded products, and their dose stays fixed until the pellet dissolves.

Transdermal and vaginal routes carry particular weight in risk decisions, because they avoid the liver effects that drive the clot risk of oral estrogen.

FDA-Approved and Compounded Bioidentical Hormones

Bioidentical hormones reach patients through two regulatory paths, and the distinction matters more than the bioidentical label itself. FDA-approved bioidentical products include estradiol patches, gels, sprays, oral estradiol, vaginal estradiol, oral micronized progesterone and the combined estradiol and progesterone capsule. These products undergo testing for dose accuracy, purity and consistency from batch to batch.

Compounded bioidentical hormones are mixed by a pharmacy for an individual prescription, often as creams, troches, capsules or pellets, sometimes combining several hormones in one preparation. Compounded products skip FDA review of safety and effectiveness. In 2020, the National Academies of Sciences, Engineering, and Medicine reviewed the evidence at the FDA's request and found limited data supporting compounded bioidentical hormone therapy. The committee advised prescribers to reserve compounded products for two situations: an allergy to an ingredient in an FDA-approved product, or a dose or form that no approved product offers.

Evaluation Before Hormone Therapy

Evaluation before hormone therapy decides whether hormones fit, which hormones, and by which route. A thorough evaluation covers the following areas:

• Symptom burden and stage. Hot flashes, night sweats, sleep loss, vaginal symptoms and mood changes, and whether a woman is in perimenopause, menopause or postmenopause.
• Age and timing. Age and years since the final period, which shape the benefit-risk balance more than any other factor.
• Personal history. Breast and other estrogen-sensitive cancers, blood clots, stroke, heart attack, liver disease and unexplained vaginal bleeding.
• Family history and cardiovascular profile. Lipid markers, blood pressure and inflammatory markers inform route and dose.
• Look-alike drivers. Thyroid conversion, insulin and blood sugar, and nutrient status, which produce symptoms that hormones do not fix.

What Changed With the 2025 FDA Label Update

The FDA changed how it labels menopausal hormone therapy in late 2025, and most hormone therapy information online predates the change. On November 10, 2025, the agency announced the removal of the boxed warnings on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, and later approved updated labeling for a first group of products. Officials cited evidence that risks stay low when therapy starts before age 60 and within 10 years of menopause. One boxed warning remains: women with a uterus who take estrogen need a progestogen, because unopposed estrogen raises the risk of uterine lining cancer. Critics objected that no public advisory committee reviewed the change before the announcement.

How a Root-Cause Practice Approaches Hormone Therapy

A root-cause practice treats hormone therapy as one part of a plan rather than the whole plan. Dr. Samia McCully, ND prescribes bioidentical hormones and thyroid medication herself at Wellness Architecture in Menlo Park. Before and alongside hormones, she assesses blood sugar and insulin, thyroid conversion, gut health, hidden infections and nutrient status, using a 20-marker panel that includes a complete thyroid panel with free T3 and reverse T3, fasting insulin, hemoglobin A1C and ferritin. Every patient also wears a continuous glucose monitor. Starter programs run 5 to 16 weeks. One published patient account from the practice describes coming off hormones, no longer having hot flashes and losing 20 pounds after a five-week program; individual results vary.

Benefits and Limits of Hormone Therapy

Hormone therapy remains the most effective treatment for hot flashes and night sweats, and its benefits extend to bone, sleep and genitourinary health. The main benefits are:

1. Vasomotor relief. Estradiol reduces the frequency and severity of hot flashes and night sweats. In placebo-controlled trials of estradiol gel, the higher dose produced a significant reduction by week 4, with the full effect building over about 12 weeks.
2. Bone protection. The Menopause Society lists prevention of bone loss among the main indications, a benefit that matters most in the years of fastest loss around the final period.
3. Genitourinary comfort. Vaginal estrogen restores tissue and eases dryness, painful sex and urinary urgency.
4. Sleep. Fewer night sweats and the bedtime effect of oral micronized progesterone both support sleep continuity.
5. Replacement after early menopause. Women whose menopause arrives before 45, naturally or surgically, receive hormones to replace years of lost estrogen.

The limits matter as much as the benefits. Hormone therapy does not correct an underactive thyroid, insulin resistance, iron deficiency or poor sleep from other causes. Fatigue, weight gain and brain fog driven by those conditions persist on hormones until the underlying driver receives treatment.

Bioidentical Hormones Match the Molecular Structure of the Hormones the Ovaries Make

Bioidentical describes chemistry: a bioidentical hormone has exactly the molecular structure of the hormone the ovaries produce. 17-beta estradiol and progesterone are the core bioidentical hormones. Older regimens relied on conjugated equine estrogens, derived from horse urine, and synthetic progestins such as medroxyprogesterone acetate, which differ in structure from human hormones. Matching structure means the body processes bioidentical hormones through its normal pathways. The label says nothing about source, dose or regulation, so an FDA-approved patch and a compounded cream both qualify as bioidentical.

FDA-Approved Bioidentical Estradiol and Progesterone Products Exist Alongside Compounded Versions

FDA-approved bioidentical options cover most needs. Estradiol comes as FDA-approved patches, gels, sprays, tablets and vaginal products; micronized progesterone comes as an FDA-approved capsule; and since 2018, a single FDA-approved capsule combines both. These products give a prescriber a standardized, batch-tested starting point. Compounded preparations fill the remaining gaps, such as an allergy to an inactive ingredient or a dose that approved products do not offer.

Women With a Uterus Need Progesterone Alongside Estrogen to Protect the Uterine Lining

Estrogen stimulates the uterine lining to grow, and without a progestogen that growth raises the risk of endometrial hyperplasia and endometrial cancer. Women who still have a uterus therefore take progesterone or another progestogen whenever they use systemic estrogen. Oral micronized progesterone serves this role in bioidentical regimens. This rule survived the 2025 FDA label change as the one remaining boxed warning on menopausal estrogen products. Women who have had a hysterectomy take estrogen alone.

Transdermal Estradiol Carries a Lower Clot Risk Than Oral Estrogen

Route changes risk. Oral estrogen passes through the liver before reaching the rest of the body, which increases production of clotting factors and raises the risk of deep vein thrombosis and stroke. Transdermal estradiol, delivered through a patch, gel or spray, bypasses that first pass. The Menopause Society's 2022 position statement notes that lower doses and transdermal routes reduce the risk of blood clots and stroke. For women with higher baseline clot risk, the route decision carries as much weight as the decision to treat.

The FDA Moved in 2025 to Remove Boxed Warnings on Heart Disease, Breast Cancer and Dementia

The boxed warnings that followed the 2002 Women's Health Initiative report shaped two decades of fear about hormone therapy. Reanalysis of the WHI showed that age and timing changed the picture: women who started therapy in their 50s did not show the heart risk seen in women who started in their 70s. Long-term WHI follow-up published in JAMA in 2020 found that estrogen alone, in women who had a hysterectomy, lowered breast cancer incidence (0.30 percent per year versus 0.37 percent with placebo) and breast cancer deaths, while estrogen plus a synthetic progestin raised incidence. In November 2025, the FDA announced removal of the boxed warnings on cardiovascular disease, breast cancer and probable dementia.

Frequently Asked Questions About Bioidentical Hormone Therapy

What Are Bioidentical Hormones?

Bioidentical hormones have the same molecular structure as the hormones the ovaries produce, mainly 17-beta estradiol and progesterone. They come as FDA-approved products, such as estradiol patches and micronized progesterone capsules, and as compounded preparations mixed by a pharmacy.

Is Hormone Replacement Therapy Safe?

For healthy women under 60 or within 10 years of menopause, The Menopause Society's 2022 position statement finds that the benefits outweigh the risks for treating hot flashes and preventing bone loss. Safety depends on age, timing, health history, dose and route.

Which Women Need Alternatives to Hormone Therapy?

Women with unexplained vaginal bleeding, a history of estrogen-sensitive cancer such as breast cancer, a prior stroke, heart attack or blood clot, or active liver disease generally need other treatment options. A full health history review comes before any prescription.

How Long Does It Take for Hormone Therapy to Work?

Hot flashes and night sweats begin to ease within the first few weeks of estradiol therapy. In placebo-controlled gel trials, significant reductions appeared by week 4, with the full effect building over about 12 weeks. Dose adjustments during follow-up fine-tune the response.

Are Compounded Bioidentical Hormones Better Than FDA-Approved Hormones?

No evidence shows that compounded hormones work better. The National Academies' 2020 review found limited safety and effectiveness data and advised reserving compounded hormones for allergies to approved products or doses no approved product offers.

Common Misconceptions About Bioidentical Hormone Therapy

Misconception: Bioidentical Means Compounded

Bioidentical describes molecular structure, not where a product comes from. FDA-approved estradiol patches, gels and micronized progesterone capsules are bioidentical. Compounded preparations form a separate, less regulated category within bioidentical therapy.

Misconception: Hormone Therapy Causes Breast Cancer in Every Woman Who Takes It

Breast cancer risk depends on the regimen, duration and individual history. In long-term WHI follow-up, estrogen alone in women after hysterectomy lowered breast cancer incidence, while estrogen plus a synthetic progestin raised it. The FDA moved in 2025 to remove the breast cancer boxed warning.

Misconception: Natural Hormones Carry No Risk

Bioidentical hormones act on the body exactly as the body's own hormones do, so they carry real effects and real risks. Unopposed estrogen thickens the uterine lining, and oral estrogen raises clot risk, whatever the source or label of the product.

Misconception: It Is Too Late to Consider Hormone Therapy After Perimenopause

The most favorable benefit-risk balance applies before age 60 or within 10 years of menopause, which covers many postmenopausal women. Women beyond that window still use low-dose vaginal estrogen for genitourinary symptoms, with minimal absorption into the bloodstream.

Misconception: Hormone Therapy Alone Resolves Every Midlife Symptom

Hormone therapy treats symptoms driven by falling estrogen and progesterone. Fatigue, weight gain and brain fog also arise from thyroid problems, insulin resistance and nutrient deficiencies, which hormones leave untouched until those drivers receive their own treatment.

Ongoing Debates in Bioidentical Hormone Therapy

Compounded versus FDA-approved products remains the central debate. Compounding advocates value custom doses and combinations for women who react poorly to standard products. The National Academies and major menopause societies favor FDA-approved bioidentical products for consistent dosing and oversight.

The 2025 FDA label change drew both support and criticism. Supporters argue the old boxed warnings overstated risk for younger women and deterred appropriate treatment. Critics objected that the agency announced the change without a public advisory committee review.

Pellet therapy divides clinicians. Users value months of hormone delivery from a single in-office procedure. Critics point to hormone levels that run high and stay high once a pellet is placed.

Duration of therapy remains unsettled. One position supports individualized long-term use while benefits continue and risks stay low. The other favors the shortest duration that controls symptoms, citing sparse trial data beyond age 60 to 65.

Testosterone for women attracts strong claims. Advocates describe broader benefits for energy, mood and muscle. Current guideline support covers low sexual desire in postmenopausal women specifically.

Components of Bioidentical Hormone Therapy

Bioidentical hormone therapy assembles several components into one regimen. Estradiol forms the core component of menopausal hormone therapy, carrying the benefits for hot flashes, bone and vaginal tissue. Progesterone forms the protective component of combined therapy for women with a uterus, keeping the uterine lining stable while estradiol works elsewhere. The delivery route adds its own components: a skin patch, as the standard transdermal vehicle, steadies estradiol levels and sidesteps the liver. On the symptom side, hot flashes and night sweats make up vasomotor symptoms, the primary target of treatment. Evaluation contributes a final component, the health history review, which screens for contraindications and identifies the thyroid, blood sugar and nutrient drivers that hormones leave in place.

Summary

Bioidentical hormone therapy uses estradiol and progesterone with the same structure as ovarian hormones to relieve hot flashes, protect bone and restore sleep and genitourinary comfort. FDA-approved bioidentical products cover most needs, while compounded preparations serve narrower cases. Age, timing, route and health history decide the benefit-risk balance, and the 2025 FDA label change reflects evidence that risks stay low when therapy starts before 60 and within 10 years of menopause. Paired with treatment of thyroid, blood sugar and nutrient drivers, bioidentical hormone therapy addresses the full picture of the menopause transition.

Sources

• The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022.
• National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy (2020).
• The Menopause Society. Practice Pearl: Compounded bioidentical hormone therapy.
• OPB/NPR. The FDA removes a long-standing warning from hormone-based menopause drugs (November 10, 2025).
• Patient Care. FDA removes boxed warnings from select menopausal hormone therapy labels.
• Chlebowski RT et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA, 2020.
• Healio. FDA approves bioidentical hormone therapy for menopausal hot flashes (2018).
• Estradiol gel prescribing information, 12-week placebo-controlled trial (MedLibrary).

Free tool: Is It Too Late for Hormone Therapy? Timing Explainer →